We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00227188
Recruitment Status : Completed
First Posted : September 27, 2005
Last Update Posted : November 29, 2012
Information provided by (Responsible Party):

Brief Summary:
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Condition or disease Intervention/treatment
Invasive Pneumococcal Disease Drug: Pneumococcal 7-valent conjugate vaccine Prevnar

Study Type : Observational
Actual Enrollment : 408 participants
Time Perspective: Prospective
Official Title: Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain
Study Start Date : May 2003
Primary Completion Date : December 2005
Study Completion Date : December 2005

Group/Cohort Intervention/treatment
Children from 0-5 years of age evaluated for IPD
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR

Biospecimen Retention:   Samples Without DNA
Samples without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00227188

Pfizer Investigational Site
Bilbao, Spain, 48903
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00227188     History of Changes
Other Study ID Numbers: 0887-101317
First Posted: September 27, 2005    Key Record Dates
Last Update Posted: November 29, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs